Flash Finance

Laurus Labs LimitedLAURUSLABSCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹2,060.10
MCap ₹111,310 Cr · P/E 102.1
Laurus Labs Limited — Stock analysis & AI research Laurus Labs Limited — Multibagger AI analysis Laurus Labs Limited — Seasonality — best & worst months Laurus Labs Limited — Technical indicators & charts Laurus Labs Limited — Technical setup — score, trend, support & resistance Laurus Labs Limited — Rising Wedge pattern forming Laurus Labs Limited — Live exchange announcements
📋 High ROE Stocks📋 High Operating Margin Stocks📋 Stocks With Strong Quarterly Results📋 Large Cap Stocks List📋 Quality + Momentum Stocks 📈 New 52-Week High Stocks📈 Stocks Near 52-Week High📈 Bollinger Squeeze Stocks📈 Bullish EMA Alignment📈 Relative Strength Leaders📈 Highest Technical Score ⚖️ vs Sun Pharmaceutical⚖️ vs Zydus Lifesciences 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹2,026 Cr
Sales · Jun 2026
+29.1% YoY
₹638 Cr
Operating Profit · Jun 2026
+67.0% YoY
31.5%
OPM % · Jun 2026
+29.6% YoY
₹362 Cr
Net Profit · Jun 2026
+123.9% YoY
₹6.81
EPS · Jun 2026
+125.5% YoY

📝 Laurus Labs Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Laurus Labs Limited reported revenue of ₹2,026 crore for the quarter ended June 2026 (Q1 FY27), up 29.1% from ₹1,570 crore in the same quarter last year, and up 11.8% sequentially over the March 2026 quarter.

Net profit rose 123.9% year-on-year to ₹362 crore, from ₹162 crore. Earnings per share (EPS) came in at ₹6.81.

Operating profit stood at ₹638 crore — an operating margin (OPM) of 31.5%, compared with 24.3% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Laurus Labs Limited posted revenue of ₹6,813 crore, a growth of 22.7% over FY25, with a net profit of ₹890 crore (up 147.9% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹7,270 crore with a net profit of ₹1,090 crore.

Valuation snapshot

At the current price of ₹2,060.10, LAURUSLABS has a market capitalisation of ₹111,310 crore and a trailing P/E of about 102.1.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 6th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 27.47%, foreign institutional investors (FIIs) 28.00%, domestic institutional investors (DIIs) 13.74%, public shareholders 30.78% of Laurus Labs Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹111,310 Cr
Current Price ?
₹2,060.1
P/E ?
102.09above ind
Industry P/E ?
35.00
P/B ?
21.00
P/S ?
15.31
P/FCF ?
198.77
Enterprise Value ?
₹113,828 Cr
EV/EBITDA ?
55.97
PEG ?
25.52
Earnings Yield ?
1.4%
Dividend Yield ?
0.09%
Profitability & Returns
Sales (TTM) ?
₹7,270 Cr
OPM ?
28.0%
Profit after tax (TTM) ?
₹1,090 Cr
EPS (TTM) ?
₹20.18
ROCE ?
18.0%
ROE ?
20.6%
ROA ?
10.4%
Growth
Sales — latest qtr ?
₹2,026 Cr
PAT — latest qtr ?
₹362 Cr
YoY qtr sales growth ?
29.1%
YoY qtr profit growth ?
123.9%
Sales growth (3y) ?
4%
Sales growth (5y) ?
7%
Profit growth (3y) ?
4%
Profit growth (5y) ?
-2%
Financial Health
Debt ?
₹2,518 Cr
Debt to Equity ?
0.48
Interest Coverage ?
7.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
27.47%
Change in promoter holding ?
-0.13%
Pledged percentage ?
N/A
Market
Return 3 months ?
34.7%
Return 6 months ?
81.4%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 1,5451,3811,1821,2241,1951,4401,1951,2241,4151,7201,5701,6531,7781,8122,026 +29.1% +11.8%
Operating Profit 404286167188181241171178285421382403480512638 +67.0% +24.7%
Other Income 12422193595910276129 -12.0% -23.5%
Interest 435339425150495358565240394042 -18.0% +5.5%
Depreciation 8487919398102106108106110117120121122124 +6.0% +1.5%
Profit Before Tax 2781474154351071823131312224270327361481 +114.7% +33.3%
Net Profit 20310525372375122093234162194252282362 +123.9% +28.4%
EPS 3.781.900.460.690.431.400.230.371.714.343.023.614.675.176.81 +125.5% +31.7%
OPM % 26.1% 20.7% 14.1% 15.3% 15.2% 16.8% 14.3% 14.6% 20.2% 24.4% 24.3% 24.4% 27.0% 28.3% 31.5% +29.6% +11.3%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹5,554 Cr ₹6,813 Cr ₹7,270 Cr +22.7%
Operating Profit ₹1,055 Cr ₹1,778 Cr ₹2,034 Cr +68.4%
OPM % 19.00% 26.09% 27.97% +37.3%
NPM % 6.46% 13.06% 15.00% +102.2%
Other Income ₹75 Cr ₹55 Cr ₹54 Cr -26.6%
Depreciation ₹430 Cr ₹480 Cr ₹487 Cr +11.6%
Interest ₹216 Cr ₹170 Cr ₹161 Cr -21.2%
EBIT ₹625 Cr ₹1,298 Cr ₹1,547 Cr +107.6%
PBT ₹484 Cr ₹1,182 Cr ₹1,439 Cr +144.0%
Tax ₹130 Cr ₹213 Cr ₹269 Cr +63.7%
Net Profit ₹359 Cr ₹890 Cr ₹1,090 Cr +147.9%
EPS ₹6.65 ₹16.47 ₹20.26 +147.7%
Material Cost ₹2,668 Cr ₹2,126 Cr ₹2,309 Cr -20.3%
Employee Cost ₹720 Cr ₹660 Cr ₹704 Cr -8.3%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 108108108108 +0.0%
Reserves 3,9304,0034,3655,192 +18.9%
Borrowings 2,0152,5772,7642,518 -8.9%
Other Liabilities 1,6081,6992,0992,693 +28.3%
Total Liabilities 7,6608,3879,33610,511 +12.6%
Fixed Assets 3,4093,8904,1234,371 +6.0%
CWIP 551423458773 +68.8%
Investments 50124233309 +32.6%
Other Assets 3,6513,9504,5215,058 +11.9%
Total Assets 7,6608,3879,33610,511 +12.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 9946666021,624 +169.8%
Cash from Investing Activity -997-822-680-1,086 -59.7%
Cash from Financing Activity -2725039-525 -1446.2%
Net Cash Flow -3093-3913 +133.3%
Free Cash Flow 6-1061560 +818.0%
CFO/OP 80%99%70%107% +52.9%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 96120132115 -12.9%
Inventory Days 222277285317 +11.2%
Days Payable 94158141170 +20.6%
Cash Conversion Cycle 224240276263 -4.7%
Working Capital Days 59424358 +34.9%
ROCE % 23%7%9%18% +100.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 27.60%27.60%27.49%27.49%27.47% -0.1%
FIIs 25.70%26.17%26.52%25.82%28.00% +8.4%
DIIs 11.94%11.72%12.42%13.96%13.74% -1.6%
Public 34.78%34.52%33.57%32.73%30.78% -6.0%
No. of Shareholders 2,80,2232,83,6782,80,7562,92,2812,91,653 -0.2%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Laurus Labs Limited's revenue in Q1 FY27?
Laurus Labs Limited reported revenue of ₹2,026 crore for the quarter ended June 2026 (Q1 FY27), up 29.1% from ₹1,570 crore in the same quarter last year, and up 11.8% sequentially over the March 2026 quarter.
What was Laurus Labs Limited's net profit in Q1 FY27?
Net profit rose 123.9% year-on-year to ₹362 crore, from ₹162 crore. Earnings per share (EPS) came in at ₹6.81.
What is LAURUSLABS's market capitalisation and P/E ratio?
At the current price of ₹2,060.10, LAURUSLABS has a market capitalisation of ₹111,310 crore and a trailing P/E of about 102.1.
Who owns Laurus Labs Limited? (shareholding pattern)
As of Jun 2026, promoters held 27.47%, foreign institutional investors (FIIs) 28.00%, domestic institutional investors (DIIs) 13.74%, public shareholders 30.78% of Laurus Labs Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI